AbbVie Collaborates with Genmab to Develop and Commercialize Therapies for Cancer Worth Over $3B

 AbbVie Collaborates with Genmab to Develop and Commercialize Therapies for Cancer Worth Over $3B

AbbVie Collaborates with Genmab to Develop and Commercialize Therapies for Cancer Worth Over $3B

Shots:

  • Genmab to receive $750M as up front and is eligible to receive ~$3.15B as development, regulatory & commercial milestones for all programs along with royalties (22% – 26%) on sales for epcoritamab (ex- US & Japan). The collaboration includes development and commercialization of the three bispecific Ab therapeutic candidates
  • The parties equally share pre-tax profits from the sale of products included milestones up to $1.15B related to clinical development and commercial success across the three existing bispecific Abs programs. In addition, if all four next-generation Abs emerges research collaboration are successful, Genmab is eligible to receive up to $2B as option exercising payment and milestones
  • The companies will share commercialization of epcoritamab in the US & Japan, with AbbVie to lead global commercialization while Genmab will book net sales in the territories and receive royalties on remaining global sales. The companies will share responsibilities for global development & commercialization for DuoHexaBody-CD37, DuoBody-CD3x5T4 and any emerging product in the US & Japan while jointly retain the right to co-commercialize these products outside the US and Japan. Additionally, Genmab to conduct P-I studies for these programs for which AbbVie retains the right to opt-in to program development

Click here to read full press release/ article | Ref: Genmab | Image: AbbVie

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post